On initiation or discontinuation of guselkumab in patients that are obtaining concomitant CYP450 substrates, especially People with a slender therapeutic index, consider monitoring for therapeutic effect. ????? ?????? ????????????? ???????????? ????? ???????????? ????? ????? ??????: As reviewe